RECURSION PHARMACEUTICALS, INC. (RXRX)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenue | 19,223 | 14,745 | 26,082 | 14,417 |
| Research and development | 128,636 | 129,634 | 74,600 | 73,928 |
| General and administrative | 46,653 | 54,650 | 37,757 | 31,833 |
| Cost of revenue | 20,161 | 21,829 | 12,079 | 9,199 |
| Total operating costs and expenses | 195,450 | 206,113 | 124,436 | 114,960 |
| Loss from operations | -176,227 | -191,368 | -98,354 | -100,543 |
| Other income (loss), net | 4,330 | -11,277 | 2,679 | 2,480 |
| Loss before income tax benefit | -171,897 | -202,645 | -95,675 | -98,063 |
| Income tax benefit | - | -158 | 167 | -523 |
| Net loss | -171,897 | -202,487 | -95,842 | -97,540 |
| Net loss per share of class a, b and exchangeable common stock, basic (in dollars per share) | -0.41 | -0.5 | -0.34 | -0.4 |
| Net loss per share of class a, b and exchangeable common stock, diluted (in dollars per share) | -0.41 | -0.5 | -0.34 | -0.4 |
| Weighted-average shares (class a, b and exchangeable) outstanding, basic (in shares) | 417,361,147 | 402,771,972 | 282,583,048 | 242,196,409 |
| Weighted-average shares (class a, b and exchangeable) outstanding, diluted (in shares) | 417,361,147 | 402,771,972 | 282,583,048 | 242,196,409 |